11 results about "Venetoclax" patented technology

This invention discloses a method for synthesizing a venetum intermediate, specifically as follows: Step 1: In an organic solvent, 2,4-difluorobenzoic acid and 5-hydroxy-7-azaindole undergo an etherification reaction under the action of an acid-binding agent. After the reaction, post-treatment yields 2-((1h-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-fluorobenzoic acid; Step 2: 2-((1h-pyrrolo[2,3-b]pyridin-5-yl)oxy)-4-fluorobenzoic acid reacts with 1-((2-(4-chlorophenyl)-4,4-dimethylcyclohexene-1-)methyl)piperazine in… An amination reaction occurs under the action of a base. After the reaction, post-treatment yields 2-(7-azaindole-5-oxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohexene-1-)methyl)piperazine-1-)benzoic acid, i.e., Venetantora intermediate III. The synthetic process provided by this invention avoids Grignard reactions and subsequent hydrolysis reactions, shortens the operation steps, simplifies the synthetic process, and provides a simple and easy-to-operate synthetic process. The raw materials are inexpensive and readily available, while avoiding the use of highly toxic raw materials. The production process is green and environmentally friendly, and suitable for industrial production.

Disclosed herein are combination therapies for treating hematological malignancies (e.g., acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)) using an antibody that binds human galectin-9 (anti-Gal9 antibody, e.g., G9.2-17) and one or more chemotherapeutic agents, e.g., a Bcl2 inhibitor such as venetoclax, a hypomethylating agent (HMA), or a combination thereof.

Provided are pharmaceutical combinations, pharmaceutical compositions, and methods of treatment of cancer using combinations of BH3 mimetics such as venetoclax and navitoclax with 0MA1 activators such as BTM-3566.

This application relates to methods for treating patients with reduced sensitivity to BCL-2 inhibitors. An antibody or antigen-binding fragment thereof that binds to CD70 is provided for treating myeloid malignancies in human subjects resistant to BCL-2 inhibitor treatment, and a method for treating myeloid malignancies in a subject, the method comprising (a) selecting a human subject with myeloid malignancies who has reduced sensitivity to or is refractory to BCL-2 inhibitors; and (b) administering the CD70-binding antibody or antigen-binding fragment thereof to the subject. In some embodiments, the myeloid malignancy is acute myeloid leukemia (AML). In some embodiments, the CD70-binding antibody is Cusatuzumab. In some embodiments, the BCL-2 inhibitor is co-administered with the CD70-binding antibody or antigen-binding fragment thereof. In some embodiments, the BCL-2 inhibitor is Venetoc.

Provided according to embodiments of the invention are methods of treating a disorder in a subject in need thereof that include administering to the subject an effective amount of cedazuridine, an effective amount of decitabine, and an effective amount of venetoclax, thereby treating the disorder in the subject. In some embodiments of the invention, the disorder is a hyperproliferative disorder such as a cancer. In some embodiments, the disorder is a hematological cancer such as myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), leukemia (e.g., acute myeloid leukemia), or lymphoma.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.

A combination therapy for treating a hematological malignancy (e.g., acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)) is disclosed herein using an antibody that binds to human galectin-9 (an anti-Gal9 antibody, e.g., G9.2-17) and one or more chemotherapy agents, e.g., a Bcl2 inhibitor, e.g., venetoclax, a hypomethylating agent (HMA), or a combination thereof.

The invention relates to compositions and methods for treating patients with hematological proliferative disorders with CPX-351, a liposomal composition of daunorubicin and cytarabine, and venetoclax.

The present disclosure provides methods for treating leukemia (e.g., AML) using a CLK / DYRK inhibitor and a B-cell lymphoma 2 (BCL2) inhibitor (e.g., venetoclax). Kits for use in practicing the methods are also provided.

The present invention relates to a pharmaceutical combination comprising: (C) an anti-LY75 antibody, or an antigen-binding portion thereof, wherein the antibody or antigen-binding portion thereof comprises: (c) a variable heavy chain region comprising: (iv) a first vhCDR comprising SEQ ID NO: 5; (v) a second vhCDR comprising SEQ ID NO: 6, and (vi) a third vhCDR comprising SEQ ID NO: 7; and (d) a variable light chain region comprising: (iv) a first vlCDR comprising SEQ ID NO: 8; (v) a second vlCDR comprising SEQ ID NO: 9, and (vi) a third vlCDR comprising SEQ ID NO: 10; wherein the anti-LY75 antibody or antigen-binding portion thereof further comprises a covalently bound drug, wherein the drug is DM4 or DM1; and (D) Venetoclax a pharmaceutically acceptable salt thereof, for use in the treatment of diffuse large B-cell lymphoma (DLBCL) or non-Hodgkin lymphoma in patients.